Works matching IS 01676997 AND DT 2014 AND VI 32 AND IP 1
Results: 24
Structure-activity relationship (SAR) of withanolides to inhibit Hsp90 for its activity in pancreatic cancer cells.
- Published in:
- Investigational New Drugs, 2014, v. 32, n. 1, p. 68, doi. 10.1007/s10637-013-9987-y
- By:
- Publication type:
- Article
Phase II trial of combination nab-paclitaxel, carboplatin and gemcitabine in first line therapy of advanced urothelial carcinoma.
- Published in:
- Investigational New Drugs, 2014, v. 32, n. 1, p. 188, doi. 10.1007/s10637-013-0054-5
- By:
- Publication type:
- Article
Phase I, dose-finding study of AZD8931, an inhibitor of EGFR (erbB1), HER2 (erbB2) and HER3 (erbB3) signaling, in patients with advanced solid tumors.
- Published in:
- Investigational New Drugs, 2014, v. 32, n. 1, p. 145, doi. 10.1007/s10637-013-9963-6
- By:
- Publication type:
- Article
Targeted inhibition of Hsp90 by ganetespib is effective across a broad spectrum of breast cancer subtypes.
- Published in:
- Investigational New Drugs, 2014, v. 32, n. 1, p. 14, doi. 10.1007/s10637-013-9971-6
- By:
- Publication type:
- Article
Preclinical analysis of resistance and cross-resistance to low-dose metronomic chemotherapy.
- Published in:
- Investigational New Drugs, 2014, v. 32, n. 1, p. 47, doi. 10.1007/s10637-013-9974-3
- By:
- Publication type:
- Article
Ring-substituted analogs of 3,3′-diindolylmethane (DIM) induce apoptosis and necrosis in androgen-dependent and -independent prostate cancer cells.
- Published in:
- 2014
- By:
- Publication type:
- Journal Article
Antitumor activity of semisynthetic derivatives of Aconitum alkaloids.
- Published in:
- Investigational New Drugs, 2014, v. 32, n. 1, p. 60, doi. 10.1007/s10637-013-9986-z
- By:
- Publication type:
- Article
Multi-drug inhibition of the HER pathway in metastatic colorectal cancer: Results of a phase I study of pertuzumab plus cetuximab in cetuximab-refractory patients.
- Published in:
- Investigational New Drugs, 2014, v. 32, n. 1, p. 113, doi. 10.1007/s10637-013-9956-5
- By:
- Publication type:
- Article
Ring-substituted analogs of 3,3′-diindolylmethane (DIM) induce apoptosis and necrosis in androgen-dependent and -independent prostate cancer cells.
- Published in:
- Investigational New Drugs, 2014, v. 32, n. 1, p. 25, doi. 10.1007/s10637-013-9979-y
- By:
- Publication type:
- Article
Regorafenib in Japanese patients with solid tumors: phase I study of safety, efficacy, and pharmacokinetics.
- Published in:
- Investigational New Drugs, 2014, v. 32, n. 1, p. 104, doi. 10.1007/s10637-013-9953-8
- By:
- Publication type:
- Article
Preclinical studies of targeted therapies for CD20-positive B lymphoid malignancies by Ofatumumab conjugated with auristatin.
- Published in:
- Investigational New Drugs, 2014, v. 32, n. 1, p. 75, doi. 10.1007/s10637-013-9995-y
- By:
- Publication type:
- Article
A phase I schedule dependency study of the aurora kinase inhibitor MSC1992371A in combination with gemcitabine in patients with solid tumors.
- Published in:
- Investigational New Drugs, 2014, v. 32, n. 1, p. 94, doi. 10.1007/s10637-013-9950-y
- By:
- Publication type:
- Article
A Phase II multicenter, open-label, clinical and pharmokinetic trial of PM00104 in patients with advanced Ewing Family of Tumors.
- Published in:
- Investigational New Drugs, 2014, v. 32, n. 1, p. 171, doi. 10.1007/s10637-013-0037-6
- By:
- Publication type:
- Article
2-aminothiophene-3-carboxylic acid ester derivatives as novel highly selective cytostatic agents.
- Published in:
- Investigational New Drugs, 2014, v. 32, n. 1, p. 200, doi. 10.1007/s10637-013-9981-4
- By:
- Publication type:
- Article
Acknowledgement of Reviewers 2012.
- Published in:
- Investigational New Drugs, 2014, v. 32, n. 1, p. 211, doi. 10.1007/s10637-013-0058-1
- Publication type:
- Article
Rhodamine-marked bombesin: a novel means for prostate cancer fluorescence imaging.
- Published in:
- Investigational New Drugs, 2014, v. 32, n. 1, p. 37, doi. 10.1007/s10637-013-9975-2
- By:
- Publication type:
- Article
Safety, pharmacokinetics, and pharmacodynamics of the DR5 antibody LBY135 alone and in combination with capecitabine in patients with advanced solid tumors.
- Published in:
- Investigational New Drugs, 2014, v. 32, n. 1, p. 135, doi. 10.1007/s10637-013-9952-9
- By:
- Publication type:
- Article
Phase I dose-escalating study of TAS-106 in combination with carboplatin in patients with solid tumors.
- Published in:
- Investigational New Drugs, 2014, v. 32, n. 1, p. 154, doi. 10.1007/s10637-013-9964-5
- By:
- Publication type:
- Article
Feasibility of adding everolimus to carboplatin and paclitaxel, with or without bevacizumab, for treatment-naive, advanced non-small cell lung cancer.
- Published in:
- Investigational New Drugs, 2014, v. 32, n. 1, p. 123, doi. 10.1007/s10637-013-9958-3
- By:
- Publication type:
- Article
Phase 1 dose-escalation, pharmacokinetic, and cerebrospinal fluid distribution study of TAK-285, an investigational inhibitor of EGFR and HER2.
- Published in:
- Investigational New Drugs, 2014, v. 32, n. 1, p. 160, doi. 10.1007/s10637-013-9988-x
- By:
- Publication type:
- Article
A first-in-human dose-escalation study of ME-143, a second generation NADH oxidase inhibitor, in patients with advanced solid tumors.
- Published in:
- Investigational New Drugs, 2014, v. 32, n. 1, p. 87, doi. 10.1007/s10637-013-9949-4
- By:
- Publication type:
- Article
A phase II trial of AS1411 (a novel nucleolin-targeted DNA aptamer) in metastatic renal cell carcinoma.
- Published in:
- Investigational New Drugs, 2014, v. 32, n. 1, p. 178, doi. 10.1007/s10637-013-0045-6
- By:
- Publication type:
- Article
Tetrahydrofurofuran-type lignans inhibit breast cancer-mediated bone destruction by blocking the vicious cycle between cancer cells, osteoblasts and osteoclasts.
- Published in:
- Investigational New Drugs, 2014, v. 32, n. 1, p. 1, doi. 10.1007/s10637-013-9969-0
- By:
- Publication type:
- Article
Vorinostat and bortezomib as third-line therapy in patients with advanced non-small cell lung cancer: a Wisconsin Oncology Network Phase II study.
- Published in:
- Investigational New Drugs, 2014, v. 32, n. 1, p. 195, doi. 10.1007/s10637-013-9980-5
- By:
- Publication type:
- Article